Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Development of DOTA-Rituximab to be Labeled with 90Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma.

Johari Doha F, Rahmani S, Rikhtechi P, Rasaneh S, Sheikholislam Z, Shahhosseini S.

Iran J Pharm Res. 2017 Spring;16(2):619-629.

2.

Novel agents for the treatment of childhood leukemia: an update.

Eryılmaz E, Canpolat C.

Onco Targets Ther. 2017 Jul 4;10:3299-3306. doi: 10.2147/OTT.S126368. eCollection 2017. Review.

3.

Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.

Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K.

ScientificWorldJournal. 2014;2014:368947. doi: 10.1155/2014/368947. Epub 2014 Jun 19.

4.

An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS; Snehlata, Malhotra A.

Indian J Med Res. 2014 Apr;139(4):544-54.

5.

Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs.

Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D.

Int J Nanomedicine. 2014 Mar 27;9:1537-57. doi: 10.2147/IJN.S53593. eCollection 2014. Review.

6.

Biological rationale for the design of polymeric anti-cancer nanomedicines.

Zhou Y, Kopeček J.

J Drug Target. 2013 Jan;21(1):1-26. doi: 10.3109/1061186X.2012.723213. Epub 2012 Sep 26. Review.

7.

Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody.

Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD.

Mol Cancer Ther. 2012 Jun;11(6):1365-72. doi: 10.1158/1535-7163.MCT-11-0764. Epub 2012 Apr 5.

8.

Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.

Johnson RN, Kopečková P, Kopeček J.

Biomacromolecules. 2012 Mar 12;13(3):727-35. doi: 10.1021/bm201656k. Epub 2012 Feb 21.

9.

86Y based PET radiopharmaceuticals: radiochemistry and biological applications.

Nayak TK, Brechbiel MW.

Med Chem. 2011 Sep;7(5):380-8. Review.

10.

Molecular probes for the in vivo imaging of cancer.

Alford R, Ogawa M, Choyke PL, Kobayashi H.

Mol Biosyst. 2009 Nov;5(11):1279-91. doi: 10.1039/b911307j. Epub 2009 Aug 19. Review.

11.

Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

Johnson RN, Kopecková P, Kopecek J.

Bioconjug Chem. 2009 Jan;20(1):129-37. doi: 10.1021/bc800351m.

12.

Radioimmunotherapy for Non-Hodgkin's Lymphoma.

Rao AV, Akabani G, Rizzieri DA.

Clin Med Res. 2005 Aug;3(3):157-65. Review.

Supplemental Content

Support Center